TY - JOUR T1 - Knowledge and attitudes about HIV pre-exposure prophylaxis: Evidence from in-depth interviews and focus group discussions with policy makers, healthcare providers, and end-users in Lesotho JF - medRxiv DO - 10.1101/2022.06.21.22276722 SP - 2022.06.21.22276722 AU - Pascal Geldsetzer AU - Joy J. Chebet AU - Tapiwa Tarumbiswa AU - Rosina Phate-Lesihla AU - Chivimbiso Maponga AU - Esther Mandara AU - Till Bärnighausen AU - Shannon A. McMahon Y1 - 2022/01/01 UR - http://medrxiv.org/content/early/2022/06/22/2022.06.21.22276722.abstract N2 - Studies on PrEP knowledge and attitudes have mostly focused on key populations in North America and Europe. To inform Lesotho’s national rollout of PrEP to the general population, this research aimed to characterize knowledge and attitudes towards PrEP among policy makers, implementing partners, healthcare providers, and PrEP end-users in Lesotho. Respondents were purposively selected to participate based on personal experience in the development and implementation of Lesotho’s PrEP program, or the personal use of PrEP. We conducted 106 in-depth interviews with policy makers (n=5), implementing partners (n=4), and end-users (current PrEP users = 55; former PrEP users = 36; and PrEP “decliners” = 6). In addition, we held 11 focus group discussions (FGDs) with a total of 105 healthcare providers. Interview and FGD transcripts were analyzed following the tenets of Grounded Theory. Respondents expressed positive attitudes towards PrEP, owing to experienced and perceived personal, familial, and societal benefits. PrEP was viewed as i) an opportunity for serodiscordant couples to remain together, ii) a means of conceiving children with minimized risk of HIV infection, iii) providing a sense of agency and control, and iv) an avenue for addressing the HIV epidemic in Lesotho. Respondents demonstrated understanding of PrEP’s intended use, eligibility requirements, and modality of use. However, they also reported that several important misconceptions of PrEP were common among adults in Lesotho, including the belief that PrEP protects against sexually transmitted infections other than HIV, promotes promiscuity, prevents pregnancy, causes seroconversion, and provides lifelong protection from taking the pill just once. In addition to building on the perceived advantages of PrEP to shape a positive message, Lesotho’s national rollout of PrEP will likely benefit from a communication strategy that specifically addresses the common misconceptions of PrEP identified in this study.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by the Alexander-von-Humboldt Foundation University Professorship to TB (no grant number; https://www.humboldt-foundation.de/en/). PG is a Chan Zuckerberg Biohub investigator (no grant number; https://www.czbiohub.org). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval for this research was granted by the Lesotho Ministry of Health ethical committee (ID03-2019) and Heidelberg University (S-865/2018). Written informed consent was obtained from all study participants after the interviewer read out the content of the consent form and explained the purpose of the study. Those unable to provide a signature provided a thumbprint instead. The study did not include any minors.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors. ER -